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Sir,
Despite the initial success of imatinib (Gleevec, STI571) in the
treatment of chronic myeloid leukaemia (CML) (Druker et al,
1996), only few patients achieve a complete molecular remission,
with just 4% displaying consistent PCR-negative status by 30
months in the IRIS trial (Hughes et al, 2003). The source of this
residual disease and the question of whether imatinib can deplete
leukaemic stem cells have sparked a discussion (Chaudhary et al,
1991; Bedi et al, 1993; Graham et al, 2002; Jiang et al, 2004; Michor
et al, 2005; Roeder et al, 2006).
Two groups have recently published theoretical models to study
the treatment response to imatinib. Roeder et al (2006) investigated
stem cell dormancy (Graham et al,2 0 0 2 )a sam e c h a n i s mo f
imatinib insensitivity and suggested that proliferating stem cells are
depleted during therapy. In the absence of resistance mutations,
their model predicts a continuous decrease in the leukaemic cell
burden, and eventually an eradication of the disease (Glauche et al,
2006). Michor et al (2005) proposed that leukaemic stem cells are
not depleted by significant amounts during imatinib therapy. This
conclusion was drawn from the relapse dynamics in patients who
discontinue therapy; their leukaemic cell load increases to levels
beyond pretreatment baseline after stop of therapy, suggesting that
leukaemic stem cells keep expanding during treatment. We designed
the simplest possible model that can reproduce the disease
dynamics over the first 12 months of therapy. It was our intent to
model CML dynamics over the first year of imatinib therapy only
(not over the whole course of disease progression) owing to data
availability. The model does not consider competition between wild-
type and leukaemic stem cells because there is no evidence for such
interactions in the 12 months data. This model predicts an eventual
relapse in the leukaemic cell count due to continuously expanding
leukaemic stem cells. In a follow-up paper (Dingli and Michor,
2006), we investigated a model including density dependence of
wild-type and leukaemic stem cells. In that model, leukaemic stem
cells cannot expand indefinitely, but cannot be eradicated either
because they are intrinsically insensitive to imatinib. The model
reproduces the long-term imatinib response data (Figure 1) and
predicts that imatinib cannot cure CML patients.
Our models remain valid given the currently available data.
Further experimental and theoretical investigations are needed to
increase the understanding of CML stem cell dynamics and to
clarify the mechanism of their insensitivity to imatinib.
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Figure 1 Imatinib treatment dynamics. Based on Dingli and Michor
(2006), the system containing stem cells (SC), progenitor cells (PC),
differentiated (DC) and terminally differentiated cells (TC) is described by
Wildtypecells Leukaemiccells
SC . x0 ¼½ rxf   d0 x0
. y0 ¼½ ryj   d0 y0
PC . x1 ¼ axx0   d1x1
. y1 ¼ ayy0   d1y1
DC . x2 ¼ bxx1   d2x2
. y2 ¼ byy1   d2y2
TC . x3 ¼ cxx2   d3x3
. y3 ¼ cyy2   d3y3
Here f¼1/[1þcx(x0þy0)] and j¼1/[1þcy(x0þy0)] Imatinib therapy
starts on day 0 and leads to a biphasic decline of the leukaemic cell burden.
The figure shows the ratio of BCR-ABL over BCR in percent (line) and the
median values (circles) of 69 patients from the German cohort of the IRIS
trial (Glauche et al, 2006). Owing to the unavailability of the raw data, a
least squares analysis could not be performed. The leukaemic cell load
cannot be eradicated because leukaemic stem cells are insensitive to
imatinib. Parameter values are d0¼0.003, d1¼0.008, d2¼0.05, d3¼1,
ax¼0.8, bx¼5, cx¼100, ay¼3.2 before therapy and ay¼0.04 during
therapy, by¼5 before therapy and by¼0.167 during therapy, cy¼100,
rx¼0.008, ry¼1, cx¼1.67 10
 6, cy¼3 10
 4.
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